Skip to main content

Table 4 TIC-targeting drugs under clinical investigations. Adapted from [81, 125, 173–175]

From: Tumor-Initiating Cells: a criTICal review of isolation approaches and new challenges in targeting strategies

Target molecules

Therapeutics

Disease

Clinical trial

Company

Undisclosed

TIC inhibitor BB1608

CRC

Entering phase III

Boston Biomedicals, Inc

Telomerase inhibitor

IMETELSTAT

Broad range

Phase II

Geron Corporation

CD133

Dendritic cell-based vaccine ICT-121

Glioblastoma

Entering phase I

ImmunoCelllular Therapeutics Ltd

Focal adhesion kinase inhibitor

VS6063

Advanced solid tumors

Phase I completed

Verastem and Pfeizer

Wilms Tumor 1

Peptides from Wilms Tumor 1 (FPI-01)

Leukemia and

mesothelioma

Phase II

Formula Pharmaceuticals

EphA3

Human monoclonal antibody (KB004) binds EphA3

Leukemia

Phase I

KaloBios Pharmaceuticals, Inc.

Notch pathway

Anti-DLL4 (demcizumab) (OMP-21 M18)

Solid tumors

Phase II

OncoMed

Anti-Notch2/3 (OPM-59R5)

Solid tumors

Phase I

Wnt pathway

Anti-Fzd7 (OMP-18R5, vantictumab, binds 5 Frizzled receptors)

Solid tumors

Phase I

Truncated Frizzled 8-Fc fusion protein (OMP-54 F28)

Advanced solid tumors

Phase I

Undisclosed cancer stem cell antigen

Peptides vaccine (SL401 and SL701)

Advanced leukemia and advanced brain cancer

Phase I/II completed

Stemline Therapeutics